Cabaletta Bio, Inc. (CABA)
| Market Cap | 203.66M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -35.56M |
| Shares Out | 24.93M |
| EPS (ttm) | -1.52 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 26 |
| Last Price | $7.73 |
| Previous Close | $8.17 |
| Change ($) | -0.44 |
| Change (%) | -5.39% |
| Day's Open | 8.08 |
| Day's Range | 7.69 - 8.31 |
| Day's Volume | 29,332 |
| 52-Week Range | 7.05 - 16.38 |
PHILADELPHIA, May 27, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for pati...
Cabaletta Bio Inc (NASDAQ: CABA) has announced acute safety data from the first dose cohort of the ongoing DesCAARTes Phase 1 trial of DSG3-CAART for mucosal-dominant pemphigus Vulgaris (mPV). In the fi...
– Acute safety data from the first cohort in the DesCAARTes™ trial announced today; no dose limiting toxicities (DLTs) or clinically relevant adverse events observed in the first dose cohort as of April...
– No dose limiting toxicities (DLTs) or clinically relevant adverse events observed in the first dose cohort as of April 30, 2021 –
PHILADELPHIA, April 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for pa...
PHILADELPHIA, March 16, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for pa...
Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like UFP Industries (UFPI), Cabaletta Bio (CABA), Alto (PEIX), Ribbon (RBBN) and Software Acquisition...
Cabaletta Bio, Inc. is a clinical-stage biotechnology company aiming to develop engineered T-cell therapies for B-cell-mediated autoimmune diseases. Cabaletta has 3 potential therapeutics from its thera...
First patient ever infused with a CAAR (chimeric autoantibody receptor) T cell therapy product candidate expands the potential clinical application of CAR T technology beyond cancer into autoimmune dise...
PHILADELPHIA, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for pat...
PHILADELPHIA, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for pat...
PHILADELPHIA, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for ...
PHILADELPHIA, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for p...
PHILADELPHIA, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for p...
PHILADELPHIA and DENVER, July 07, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell ther...
Cabaletta Bio, Inc. (CABA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Collaboration deepens pipeline with CAAR design and optimization effort in three additional B cell-mediated autoimmune diseases
PHILADELPHIA, May 12, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for pa...
Cabaletta Bio: Curative Medicines For Autoimmunity
Cabaletta Bio, Inc. (CABA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.
Cabaletta Bio Inc. shares slid 18% in their trading debut Friday, after underwriters priced the deal at $11, a full $3 below the $14 to $16 price range.
About CABA
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune b... [Read more...]
| Industry Biotechnology | IPO Date Oct 25, 2019 |
| Stock Exchange NASDAQ | Ticker Symbol CABA |
Analyst Forecasts
According to 5 analysts, the average rating for Cabaletta Bio stock is "Strong Buy." The 12-month stock price forecast is 22.60, which is an increase of 192.37% from the latest price.